HPC
RCUS icon

HM Payson & Co’s Arcus Biosciences RCUS Stock Holding History

HM Payson & Co’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.4K Hold
1,700
– – ﹤0.01% 696
2026
Q1 		$36.7K Hold
1,700
– – ﹤0.01% 747
2025
Q4 		$40.5K Hold
1,700
– – ﹤0.01% 732
2025
Q3 		$23.1K Hold
1,700
– – ﹤0.01% 815
2025
Q2 		$13.8K Hold
1,700
– – ﹤0.01% 826
2025
Q1 		$13.3K Hold
1,700
– – ﹤0.01% 840
2024
Q4 		$25.3K Hold
1,700
– – ﹤0.01% 745
2024
Q3 		$26K Hold
1,700
– – ﹤0.01% 730
2024
Q2 		$25.9K Hold
1,700
– – ﹤0.01% 718
2024
Q1 		$32.1K Hold
1,700
– – ﹤0.01% 674
2023
Q4 		$32.5K Hold
1,700
– – ﹤0.01% 661
2023
Q3 		$30.5K Hold
1,700
– – ﹤0.01% 667
2023
Q2 		$34.5K Hold
1,700
– – ﹤0.01% 646
2023
Q1 		$31K Hold
1,700
– – ﹤0.01% 653
2022
Q4 		$35.2K Hold
1,700
– – ﹤0.01% 607
2022
Q3 		$44K Buy
1,700
+700
+70% +$18.5K ﹤0.01% 593
2022
Q2 		$25K Buy
+1,000
New +$24.5K ﹤0.01% 682

Other funds holding RCUS

TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
SAM
Seelaus Asset Management Chatham, New Jersey $142M AUM 48.54% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

HM Payson & Co's RCUS Position: Q2 2026 in Review

HM Payson & Co held its Arcus Biosciences (RCUS) position steady in Q2 2026 at 1,700 shares worth $52.4K. The position accounts for ﹤0.01% of the portfolio, ranked #696.

HM Payson & Co first reported a position in RCUS in Q2 2022 and has held it in 17 quarters since. 17 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • HM Payson & Co held 1,700 shares of Arcus Biosciences worth $52.4K as of Q2 2026.
  • HM Payson & Co left its Arcus Biosciences share count unchanged in Q2 2026.
  • Arcus Biosciences made up ﹤0.01% of HM Payson & Co's portfolio in Q2 2026, its #696 holding.
  • HM Payson & Co first reported a position in Arcus Biosciences in Q2 2022 and has held it in 17 quarters since.
  • 17 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.